Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

well as a favorable impact from foreign exchange. Global cholesterol joint venture net sales, which include VYTORIN and ZETIA, totaled $1.2 billion in the 2008 first quarter. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. Including an adjustment of an assumed 50 percent of the global cholesterol joint venture net sales, Schering-Plough's adjusted sales for the 2008 first quarter would have been $5.3 billion.

Reviewing results of the recent quarter, Hassan said the company recorded good growth from many of its leading prescription, animal health and consumer products, with strong growth in international markets partially offset by slower sales growth in the United States. U.S. sales of VYTORIN and ZETIA, the cholesterol-lowering medicines under the Merck/Schering-Plough joint venture, were down slightly versus the 2007 first quarter while remaining strong in international markets. He also noted, "The tough cost-control measures we put in place in 2007 contributed to our profit performance in the recent quarter."

Regarding the outlook for Schering-Plough, Hassan said, "We are confident about our company's future because of the transformations we have driven in every area. Today, we have a strong line of products protected by long periods of market exclusivity. We have geographic and business diversity, with nearly 70 percent of our GAAP net sales coming from outside the United States. We have a rich late-stage pipeline. We have a resilient and tested work force." Added Hassan: "Our team overcame enormous challenges in 2003 and 2004. Those challenges were much bigger than the ones we face today. We are determined to power through."

Hassan observed that Schering-Plough has undergone a remarkable transformation over the past five years. Adhering to a five-phase Action Agenda, it has become a broad-based health care company with growing strengths across its bus
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Stent retriever thrombectomy, an ... in the brain reduced disability after stroke, according ... MD, President of the Society of Vascular and ... a giant step forward that will change the ... patients," said Jovin, who is associate professor of ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... commercializing proven cancer therapies in new orphan drug ... 106th Annual Meeting of the American Association ... the potential for its lead product candidate ...
(Date:4/20/2015)... and Champaign, IL (PRWEB) April 20, 2015 ... the establishment of its 12th clinical research site: PMG ... Research has assumed operation of the clinical research department ... PMG’s footprint outside the Southeast to a second region ... a 150 multi-specialty physician practice enhances PMG’s access to ...
(Date:4/20/2015)... 20, 2015 Orthobiologics are substances ... injuries. The orthobiologics market is a rewarding market, which ... The global orthobiologics market report defines and segments the ... global orthobiologics market was valued at $5,712.4 million in ... 2019, at a CAGR of 6.7% from 2014 to ...
Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) invites ... of the company,s 2008 investor meeting. The,corporate presentation ... Time on Thursday, March 13, 2008. The meeting ... of Jazz Pharmaceuticals, senior management team will provide ...
... Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") ... December 31, 2007., "2007 was our most ... the Company,s clinical trial program for REOLYSIN(R) with,Phase ... expanded and,initiated," said Dr. Brad Thompson, President and ...
... 6 Pathway Medical Technologies,which is developing innovative medical ... Buckman has been named as the new,Chairman of the ... been,acting Board Chairman since late 2006., "We are ... He brings,an extensive range of industry experience to the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... antitumor drug could, in theory, shorten patients, long-term survival, comes ... suggests a potentially better option. The study appears in the ... (online April 27). Many cancer treatments work ... growing tumors. Agents that block a vessel-promoting factor called VEGF ...
... Philip E. Bourne, a computational biologist and professor with ... with the 2009 Benjamin Franklin Award this week in ... the free and open dissemination of science and scientific ... April 28, at the annual meeting of the Bioinformatics ...
... international agencies, including the director of the U.S. ... of cooperation that could reduce the number of ... The agreement between the United States, Canada, Japan ... scientific recommendations on alternative toxicity testing methods that ...
Cached Biology News:A longer lasting tumor blocker 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 3Countries unite to reduce animal use in product toxicity testing worldwide 2Countries unite to reduce animal use in product toxicity testing worldwide 3
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Inquire...
... Isoaspartate Detection Kit is intended for quantitative ... and peptides, which can result from the ... of aspartic acid residues during storage or ... on the monitoring of charge differences for ...
...
Biology Products: